The global medical marijuana market was valued at USD 19.7 billion in 2025 and is estimated at USD 23.4 billion in 2026. It is projected to reach USD 67.8 billion by 2033, a CAGR of 16.4% over 2026-2033. North America holds the largest share at 69.5%. Oil and tinctures lead by product type at 55.6%, and chronic pain leads by application at 27.5%.

How Big Is the Medical Marijuana Market, and How Fast Is It Moving?

The jump from USD 19.7 billion in 2025 to USD 23.4 billion in 2026 is roughly 18.8% in a single year, faster than the 16.4% long-run CAGR. Early-forecast growth is running ahead of the average, which suggests demand is accelerating while the regulatory environment is still loosening.

Over the full forecast, the market is expected to add about USD 44.4 billion between 2026 and 2033. By 2033 it would be roughly 3.4 times its 2025 size. Few pharmaceutical-adjacent categories show a multiple like that, and it reflects expansion from a small base, which is why the numbers look so steep.

The figures in this article draw on Grand View Research’s market analysis. Continue your research with their Prism AI tool for more data and insights.

Why Does the April 2026 Rescheduling Matter?

The most significant development in the report is regulatory. In April 2026, the U.S. Department of Justice and the DEA moved state-licensed medical marijuana and FDA-approved cannabis from Schedule I to Schedule III. The Department of Justice also set up a streamlined DEA registration process for state-licensed medical cannabis businesses.

Rescheduling does not make cannabis broadly legal at the federal level, but it changes how the industry operates. A Schedule III classification generally means easier clinical research, clearer compliance pathways and less legal risk for operators. That supports the report’s expectation that consolidation and acquisitions among producers will drive expansion. A related signal came in May 2025, when the U.S. approved new growers of research marijuana for the first time in over 50 years, widening the capacity to study the drug’s medical value.

The caveat is that the FDA has not approved marketing cannabis itself for any disease or condition. It has approved one cannabis-derived drug, Epidiolex (cannabidiol), and three synthetic cannabis-related products: Marinol and Syndros (dronabinol) and Cesamet (nabilone). All are prescription-only. The gap between a rapidly growing market and a narrow set of approved drugs is a defining tension in this industry.

Download a free sample report or claim your copy of this full market intelligence report

Which Product Form Leads: Oils and Tinctures or Flower?

Oils and tinctures lead with a 55.6% share. Applied to the 2025 market size, that works out to roughly USD 10.9 billion, an approximate figure derived from the report’s numbers. Three reasons explain the lead.

Flower is expected to grow more slowly, though new launches may help. In 2025, wellness company Awshad launched a 6500 mg CBD oil aimed at chronic pain, cancer, epilepsy, anxiety and insomnia. Product development is concentrating on concentrated, condition-specific oils rather than traditional flower.

Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs

Which Conditions Drive Demand?

Chronic pain is the largest application at roughly 27.5% of the market, or about USD 5.4 billion on 2025 figures (again an approximation). Research describes medical cannabis as a safe option for chronic and neuropathic pain, and a growing number of clinical trials target these conditions. Patient demand for alternatives to conventional pain management is the underlying driver. In New York, for example, patients certified by a healthcare professional and registered with the state Department of Health can use medical marijuana for pain management.

The more interesting story is at the other end of the ranking. Amyotrophic lateral sclerosis (ALS) is expected to be the fastest-growing application. Rising ALS prevalence, more research on cannabinoid therapies for neurological disorders and a focus on symptom management and quality of life are cited as reasons. The report treats cannabis here as a complementary option, not a cure, which is how patients and clinicians increasingly frame it. The wider application list also covers cancer, epilepsy, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, PTSD, glaucoma, migraines and depression and anxiety.

Where Is Growth Happening: North America or Asia Pacific?

North America is the largest market with a 69.5% share in 2025, roughly USD 13.7 billion on that basis. The report notes that 37 U.S. states and the District of Columbia have legalized cannabis for therapeutic use, and ten other states have also legalized recreational use.

Asia Pacific is expected to grow fastest over 2026-2033. Favorable government initiatives, rising disposable income, growing social acceptance and awareness, and a growing population with chronic illnesses such as Parkinson’s, Alzheimer’s, cancer and neurological disorders all contribute. This is a catch-up pattern: North America has the revenue, and Asia Pacific has the growth rate.

Europe is moving too. Germany’s authorization of medical cannabis under its healthcare system has widened patient access and supported demand across the region. In late 2025, Bosnia and Herzegovina legalized medical cannabis with a regulated framework for patient access. Each new national framework adds a market, which is why legalization is the single most important growth variable.

What Holds the Market Back?

The main restraint is inconsistent regulation. Rules differ between countries and between states within a country. Licensing for cultivation, distribution, prescription and quality control is cumbersome, and the lack of uniform standards makes international trade difficult. For a new entrant, legal risk can outweigh market opportunity. This also explains why compliance and product standardization show up as competitive differentiators.

Who Competes, and What Sets Players Apart?

Profiled companies include Tilray Brands, Aurora Cannabis, Canopy Growth, Aphria, Maricann Group, Tikun Olam, MedReleaf, GW Pharmaceuticals, Cannabis Sativa, Inc. and Medical Marijuana, Inc. Their strategies center on mergers and acquisitions, partnerships, funding and product launches. The report’s analyst perspective points to advanced cultivation technology, pharmaceutical-grade products, robust distribution networks and formulations tailored to specific conditions as the differentiators.

Explore the full list of profiled companies operating in this market with recent strategic initiatives

The Bottom Line

The market is growing because three things are happening at once: legalization is spreading, clinical evidence is building, and U.S. federal policy shifted in April 2026. Oils and tinctures and chronic pain dominate today, while ALS and Asia Pacific point to where growth may come from next. The main risk to the forecast is regulatory fragmentation, not a lack of patient demand.

Check Out Our Dedicated Business Offerings –

U.S. Healthcare Facility Mapping & Intelligence Platform: Get facility-level intelligence to guide smarter decisions. Sign up Today

 


Google AdSense Ad (Box)

Comments